From 2016 to 2021 the European Treatment and Outcomes Study (EUTOS) for CML has explored the use of the newly available cell-based secondary BCR::ABL1 reference panels to assign and validate CFs for testing laboratories. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.